Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.66 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856817 | 0.90 | TRPV1 (0.69) | TRPV1MAPK3MAOAKCNH2 | |
| SCHEMBL1865975 | 0.89 | TRPV1 (0.67) | TRPV1MAPK3MAOAKCNH2 | |
| SCHEMBL12664967 | 0.89 | TRPV1 (0.55) | TRPV1MAPK3SCN9ACCNT1CCNK | |
| SCHEMBL1865465 | 0.88 | TRPV1 (0.65) | TRPV1MAPK3 | |
| SCHEMBL1862327 | 0.87 | TRPV1 (0.52) | TRPV1MAPK3SCN9AMAOAKCNH2 | |
| SCHEMBL1858238 | 0.85 | TRPV1 (0.65) | TRPV1MAPK3MAOAKCNH2 | |
| SCHEMBL1860029 | 0.84 | TRPV1 (0.59) | TRPV1MAPK3SCN9A | |
| SCHEMBL1863478 | 0.84 | TRPV1 (0.74) | TRPV1MAPK3 | |
| SCHEMBL1865540 | 0.83 | TRPV1 (0.51) | TRPV1SCN9ACDK2 | |
| SCHEMBL1860822 | 0.81 | TRPV1 (0.70) | TRPV1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | TRPV1 549/4885MAPK3 2884/4885SCN9A 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.